Entheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US

DNA molecule - entheon

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced its Psychedelics Genetic Test Kit, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc. (“HaluGen”), is now available for sale in the United States. The Psychedelics Genetic Test Kit, a […]

Read More…

Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group

Pine Point Mining signs agreement

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement (the “Agreement“) with Laboratorium Ofichem BV (“Ofichem” or “Ofichem Group”). Under the terms of the Agreement, Ofichem will supply Entheon with GMP quality N,N-dimethyltryptamine […]

Read More…

Entheon Biomedical Corp. Provides Corporate Update

DNA molecule - entheon

Launch of Psychedelics DNA Test Kit Phase 1 clinical trial for DMT progressing as planned Pre-clinical In Vivo work scheduled to start at Israeli CRO Strengthened expertise focused on driving initiatives forward Upgraded OTC Listing Financial Update Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (OTCQB: ENTBF) (“Entheon” or the “Company”), a biotechnology company focused on […]

Read More…

Entheon Biomedical Lists on OTCQB Venture Market

OTCQX stock market visual

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: “1XU1”) (“Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has been approved for trading on the OTCQB Venture Market (“OTCQB”) effective May 5, 2021. “We are thrilled to be up-listing on to the OTCQB, […]

Read More…

Entheon Biomedical Corp. Launches HaluGen’s Psychedelics Genetic Test

DNA molecule - entheon

HaluGen’s DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces the launch of the industry’s first Psychedelics Genetic Test Kit, developed by wholly-owned subsidiary, HaluGen Life Sciences […]

Read More…